NitroMed’s BiDil XR Will Use Elan Delivery Technology Under Recent Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration centers on use of Elan’s proprietary oral controlled-release delivery technology.
You may also be interested in...
NitroMed Looks To 2010 NDA For BiDil XR
Firm decides to slash jobs, quit promotion of immediate-release BiDil to fund development and commercialization of extended-release version.
NitroMed Looks To 2010 NDA For BiDil XR
Firm decides to slash jobs, quit promotion of immediate-release BiDil to fund development and commercialization of extended-release version.
NitroMed's BiDil Approved For Heart Failure In Self-Identified Black Patients
The hydralazine/isosorbide dinitrate combination is the first approval for a race-based indication. In its recent review of BiDil, an FDA advisory committee suggested race was serving as a surrogate for genomic markers. FDA suggests further study could expand BiDil's approval beyond self-identified black patients.